{
  "meta": {
    "data_length": 1,
    "message": "Indication id ind:ema:blincyto:2 retrieved successfully",
    "request_url": "https://api.moalmanac.org/indications?indication_id=ind%3Aema%3Ablincyto%3A2",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.001824,
    "timestamp_received": "2026-11-09T16:14:21.653337Z",
    "timestamp_returned": "2026-11-09T16:14:21.655161Z",
    "trace_id": "5a04df8e-775f-4722-bcc0-dad07e0070f8"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://moalmanac.org",
    "last_updated": "2026-10-08"
  },
  "data": [
    {
      "id": "ind:ema:blincyto:2",
      "type": "Indication",
      "description": "BLINCYTO is indicated as monotherapy for the treatment of paediatric patients aged 1 month or older with Philadelphia chromosome-negative CD19 positive B-cell precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation.",
      "contributions": [
        {
          "id": "ctrb:vanallenlab:2025-08-29:0",
          "type": "Contribution",
          "description": "On 2025-02-10, the EMA published an EPAR - Assessment report - Variation that recommended revising this approval's from being indicated for pediatric patients aged 1 year or older to 1 month or older.",
          "date": "2025-08-29",
          "contributor": {
            "id": "agent:user:vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute"
          }
        },
        {
          "id": "ctrb:ema:2025-01-23:0",
          "type": "Contribution",
          "description": "Indication received approval from the European Commission.",
          "date": "2025-01-23",
          "contributor": {
            "id": "agent:org:ema",
            "type": "Agent",
            "agentType": "organization",
            "name": "European Medicines Agency",
            "description": "Regulatory agency that approves medicines for use in the European Union."
          }
        },
        {
          "id": "ctrb:vanallenlab:2024-10-20:0",
          "type": "Contribution",
          "description": "Adding EMA approvals for use to database",
          "date": "2024-10-20",
          "contributor": {
            "id": "agent:user:vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute"
          }
        }
      ],
      "reportedIn": [
        {
          "id": "doc:ema:blincyto",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Blincyto (blinatumomab) [product information]. EMA.",
          "title": null,
          "aliases": [],
          "description": "Amgen Europe B.V. Blincyto (blinatumomab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf. Revised July 2025. Accessed August 29, 2025.",
          "urls": [
            "https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf",
            "https://www.ema.europa.eu/en/medicines/human/EPAR/blincyto"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "agent:org:ema",
                "type": "Agent",
                "agentType": "organization",
                "name": "European Medicines Agency",
                "description": "Regulatory agency that approves medicines for use in the European Union."
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "Amgen Europe B.V.",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Blincyto",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "blinatumomab",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": "2015-12-07",
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "publication_date",
              "value": "2025-07-23",
              "description": "The publication date for the document."
            },
            {
              "name": "regulatory_identifier",
              "value": null,
              "description": "Identifier assigned by the regulatory agency, such as an FDA application number (e.g. NDA208716, BLA125427) or an EMA product number (e.g. EMEA/H/C/006184)."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      ],
      "extensions": [
        {
          "name": "status",
          "value": "Approved",
          "description": "Current approval status."
        },
        {
          "name": "statement description",
          "value": "The European Medicines Agency (EMA) has authorized Blincyto (blinatumomab) as a monotherapy for the treatment of pediatric patients aged 1 month or older with Philidelphia chromosome negative CD19 positive B-cell precursor acute lymphoblastic leukemia (ALL) which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplants.",
          "description": "The description text for all Statements derived from this Indication."
        }
      ]
    }
  ]
}